Clin Nucl Med. 2018 Jun;43(6):402-410. doi: 10.1097/RLU.0000000000002028.
The aim of this study was to evaluate F-FDG PET/CT compared with conventional imaging techniques in the clinical management of patients with locally advanced gastric cancer (LAGC).
A prospective study between January 2010 and December 2011 in patients with suspected LAGC was conducted in our hospital. F-FDG PET/CT, contrast-enhanced CT (CECT), endoscopic ultrasound, and laparoscopy were performed in all cases. Standard whole-body F-FDG PET/CT images were obtained centered on the stomach at 1 and 2 hours after injection of 4.0 MBq/kg of F-FDG. Findings were confirmed by histopathology or by imaging follow-up in nonoperable patients.
Fifty consecutive patients with confirmed LAGC (20 women, 30 men) with a mean ± SD age of 65.7 ± 12.1 years were included. Using Lauren classification, 24 patients were intestinal subtype, and 26 were diffuse subtype. Thirty-five patients with locoregional lymph node involvement and 22 with distant metastases were confirmed as peritoneal metastases (n = 15), retroperitoneal (n = 2) or mediastinal lymph nodes (n = 1), and liver (n = 3) or bone metastases (n = 1). Patients with signet ring carcinoma showed significantly less F-FDG uptake (P = 0.001). SUVmax correlated with tumor grading (P < 0.05). Standard and delayed F-FDG PET/CT and CECT images identified LAGC in 24, 27, and 28 of 30 patients, respectively. The sensitivity and specificity for F-FDG PET/CT and CECT to detect metastases were 68% and 100% and 64% and 93%, respectively. Contrast-enhanced CT and F-FDG PET/CT diagnosed only 6 of the 15 patients with confirmed peritoneal metastases. The impact in therapeutic management of F-FDG PET/CT and CECT was 24% and 22%, respectively. Kaplan-Meier survival curves for the LGAC showed a significant correlation between SUVmax and overall survival using an SUVmax threshold of less than 3.96 (P = 0.04).
F-FDG PET/CT should be recommended for staging of LAGC; however, F-FDG PET/CT and CECT cannot replace laparoscopy to rule out peritoneal metastases. Delayed F-FDG PET/CT images show an increase of F-FDG uptake in most cases, improving LAGC detection. The grade of F-FDG uptake represents a significant prognostic tool in this series.
本研究旨在评估氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(18F-FDG PET/CT)与常规影像学技术在局部进展期胃癌(LAGC)患者临床管理中的应用。
在我院进行了一项前瞻性研究,纳入 2010 年 1 月至 2011 年 12 月疑似患有 LAGC 的患者。所有患者均进行了 18F-FDG PET/CT、增强 CT(CECT)、内镜超声和腹腔镜检查。全身标准 18F-FDG PET/CT 图像在注射 4.0MBq/kg 18F-FDG 后 1 小时和 2 小时从胃部中心开始采集。通过组织病理学或无法手术患者的影像学随访来确认发现。
50 例连续确诊的 LAGC 患者(20 名女性,30 名男性)纳入研究,平均年龄(±标准差)为 65.7±12.1 岁。根据 Lauren 分类,24 例为肠型,26 例为弥漫型。35 例患者存在局部区域淋巴结受累,22 例患者存在远处转移,其中 15 例被证实腹膜转移,2 例为腹膜后转移,2 例为纵隔淋巴结转移,3 例为肝转移,1 例为骨转移。印戒细胞癌患者的 18F-FDG 摄取明显减少(P=0.001)。SUVmax 与肿瘤分级相关(P<0.05)。标准和延迟 18F-FDG PET/CT 和 CECT 分别在 30 例患者中的 24、27 和 28 例中识别出 LAGC。18F-FDG PET/CT 和 CECT 对转移的敏感性和特异性分别为 68%和 100%,64%和 93%。CECT 和 18F-FDG PET/CT 仅诊断出 15 例腹膜转移患者中的 6 例。18F-FDG PET/CT 和 CECT 对治疗管理的影响分别为 24%和 22%。LGAC 的 Kaplan-Meier 生存曲线显示,SUVmax 与总体生存之间存在显著相关性,SUVmax 阈值小于 3.96(P=0.04)。
18F-FDG PET/CT 应推荐用于 LAGC 分期;然而,18F-FDG PET/CT 和 CECT 不能替代腹腔镜检查来排除腹膜转移。延迟 18F-FDG PET/CT 图像显示大多数情况下 18F-FDG 摄取增加,从而提高了 LAGC 的检出率。在本系列中,18F-FDG 摄取程度代表了一个重要的预后工具。